​

Korean researchers said they have discovered a method to treat cancers that do not respond to existing anticancer drugs.

​

​

​

​

​

A new drug candidate substance that shows a therapeutic effect when cancer recurs or metastasizes because it cannot be treated with anticancer drugs has been developed and is attracting attention.

CKP Therapeutics (CEO Chan-woong Kim and Jae-ha Lee) is a bio venture that researches and develops compounds for the development of new drugs for drug-resistant cancers in order to achieve its vision of 'extending life expectancy and improving the quality of life of refractory cancer patients'. The company is developing new compounds that directly target cancer stem cells based on research achievements, technology and clinical experience accumulated over 10 years.

A research team in Korea has presented a new treatment strategy using SERCA inhibitors for the first time in the world for intractable liver cancer that does not respond to existing treatments.